Biopoin Market Report 2026

Biopoin Market Overview

• The Biopoin market growth in the historic period has been driven by clinical success of epoetin therapies, rising dialysis population • Market expansion is supported by growth in chronic renal failure cases, expansion of oncology supportive care • Growth Driver: Rising Chronic Kidney Disease Incidence Fuels Growth In The Biopoin Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Biopoin Market?

Biopoin is a biopharmaceutical product used to treat anemia, especially in adults with chronic renal failure or undergoing chemotherapy for non-myeloid cancers. It contains epoetin theta, a recombinant form of erythropoietin, which stimulates red blood cell production. Biopoin also helps alleviate anemia-related fatigue and weakness by increasing hemoglobin levels. The main indications of biopoin are anemia in chronic kidney disease, cancer-related anemia, surgical anemia, and others. Anemia in chronic kidney disease (CKD) happens when damaged kidneys produce less erythropoietin, a hormone essential for making red blood cells. This leads to reduced hemoglobin levels, causing fatigue and difficulty in maintaining oxygen levels in the body. Treatments commonly include erythropoiesis-stimulating agents, iron supplementation, and sometimes blood transfusions. Biopoin-based treatments are significant in improving the quality of life for CKD patients. It is distributed through various channels, such as hospital pharmacies, retail pharmacies, and online pharmacies, and utilized by end users including adults, geriatric, and pediatric.

What Is The Biopoin Market Growth Forecast?

The growth in the forecast period can be attributed to growth in chronic renal failure cases, expansion of oncology supportive care, increased access to biosimilar epoetins, aging population trends, focus on anemia related fatigue management. Major trends in the forecast period include rising use of erythropoiesis stimulating agents, growing anemia burden in chronic kidney disease, expansion of supportive oncology care, shift toward long acting anemia management therapies, improved quality of life focus in chronic anemia patients.

Global Biopoin Market Segmentation

1) By Indication: Anemia In Chronic Kidney Disease, Cancer-Related Anemia, Surgical Anemia, Other Indications 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics 3) By End User: Adult, Geriatric, Pediatric

What Are The Drivers Of The Biopoin Market?

The growing incidences of chronic kidney disease are expected to drive the expansion of the biopoin market going forward. Chronic kidney disease (CKD) is a long-term condition characterized by the gradual loss of kidney function, leading to the kidneys' inability to filter waste and excess fluids from the blood effectively. The incidence of chronic kidney disease is mainly due to the rising rates of diabetes, hypertension, and unhealthy diets. In chronic kidney disease (CKD), reduced erythropoietin production leads to anemia, causing fatigue and weakness. Biopoin, containing epoetin theta, stimulates red blood cell production, increasing hemoglobin levels and improving quality of life. For instance, in October 2024, according to a report published by the National Health Service, a UK-based government agency, the prevalence and severity of chronic kidney disease rise with age, with nearly half of adults aged 75 and older affected by stages 1 to 5 (48%), including more than a third who experience the more severe stages 3 to 5 (36%). Furthermore, in June 2023, according to Oxford Academic, a UK-based publishing company, from 2022 to 2032, the number of people with chronic kidney disease (CKD) in the UK is projected to rise by 4%, growing from 8.27 million to 8.61 million. Therefore, the growing incidences of chronic kidney disease boost the growth of the biopoin industry. The increasing prevalence of anemia is expected to propel the growth of the biopoin market going forward. Anemia is a condition characterized by a deficiency in the number of red blood cells or the amount of hemoglobin in the blood, leading to a reduced capacity to carry oxygen to the body's tissues. The prevalence of anemia is largely due to nutritional deficiencies as insufficient intake of iron, vitamin B12, and folate impairs red blood cell production. BioPoin enhances anemia management by providing accurate diagnostics and monitoring, making it ideal for patients with iron, vitamin B12, or folate deficiencies. It helps guide timely interventions, improving treatment efficacy and overall patient health outcomes. For instance, in April 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, approximately 30.7% of women aged 15-49 years suffered from anaemia in 2023. Therefore, the increasing prevalence of anemia is driving the growth of the biopoin industry. The growing demand for personalized medicine is expected to boost the growth of the biopoin market going forward. Personalized medicine is a healthcare approach that customizes treatments based on a person's unique genetic, environmental, and lifestyle characteristics. Advancements in genetic research enable the precise identification of disease-related genetic markers, allowing healthcare providers to deliver more effective, personalized treatments. Biopoins are designed to target specific molecular markers or mutations in a patient's disease, offering more effective, tailored treatments. This approach enhances efficacy, reduces side effects, and shifts away from a one-size-fits-all model toward personalized medicine. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based hospital and healthcare organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from 6 in 2022. Therefore, the growing demand for personalized medicine will drive the growth of the biopoin industry.

Key Players In The Global Biopoin Market

Major companies operating in the biopoin market are Teva Pharmaceutical Industries

Regional Insights

North America was the largest region in the biopoin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Biopoin Market?

The biopoin market consists of sales of pre-filled syringes and erythropoiesis-stimulating agents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Biopoin Market Report 2026?

The biopoin market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the biopoin industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.